Healthcare provider profile · identity verified

Jonathan W. Lee, MD

Internal Medicine · BELLFLOWER, CA · NPI 1790852911

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	844	313
Amlodipine Besylate	Amlodipine Besylate	476	176
Losartan Potassium	Losartan Potassium	342	120
Metformin Hcl	Metformin Hcl	327	131
Omeprazole	Omeprazole	324	124
Rosuvastatin Calcium	Rosuvastatin Calcium	274	107
Lisinopril	Lisinopril	252	101
Simvastatin	Simvastatin	232	84
Glipizide	Glipizide	217	82
Levothyroxine Sodium	Levothyroxine Sodium	189	66
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	176	52
Atenolol	Atenolol	151	55
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	151	56
Hydrochlorothiazide	Hydrochlorothiazide	131	49
Tamsulosin Hcl	Tamsulosin Hcl	130	48
Meloxicam	Meloxicam	109	52
Gabapentin	Gabapentin	108	42
Alendronate Sodium	Alendronate Sodium	107	38
Albuterol Sulfate Hfa	Albuterol Sulfate	105	61
Potassium Chloride	Potassium Chloride	105	46
Pradaxa	Dabigatran Etexilate Mesylate	105	32
Pantoprazole Sodium	Pantoprazole Sodium	102	48
Lorazepam	Lorazepam	100	24
Metoprolol Tartrate	Metoprolol Tartrate	99	42
Jardiance	Empagliflozin	93	38
Metformin Hcl Er	Metformin Hcl	93	40
Duloxetine Hcl	Duloxetine Hcl	86	42
Alprazolam	Alprazolam	83	20
Bisoprolol Fumarate	Bisoprolol Fumarate	83	32
Clopidogrel	Clopidogrel Bisulfate	79	32
Triamcinolone Acetonide	Triamcinolone Acetonide	78	44
Allopurinol	Allopurinol	76	29
Hydralazine Hcl	Hydralazine Hcl	72	33
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	72	24
Terazosin Hcl	Terazosin Hcl	70	27
Finasteride	Finasteride	63	25
Humulin N	Insulin Nph Human Isophane	62	23
Trazodone Hcl	Trazodone Hcl	58	26
Hydrocortisone	Hydrocortisone	54	28
Acetaminophen-Codeine	Acetaminophen With Codeine	50	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	50	suppressed
Cephalexin	Cephalexin	48	44
Azithromycin	Azithromycin	47	46
Mirtazapine	Mirtazapine	47	21
Prednisone	Prednisone	46	38
Furosemide	Furosemide	45	26
Ibuprofen	Ibuprofen	44	25
Ondansetron Odt	Ondansetron	42	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	38	19
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	37	37
Spiriva Respimat	Tiotropium Bromide	36	12
Tramadol Hcl	Tramadol Hcl	36	16
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	34	34
Famotidine	Famotidine	34	15
Escitalopram Oxalate	Escitalopram Oxalate	31	16
Wixela Inhub	Fluticasone Propion/Salmeterol	30	12
Benazepril Hcl	Benazepril Hcl	28	suppressed
Ketoconazole	Ketoconazole	28	14
Pravastatin Sodium	Pravastatin Sodium	28	12
Eliquis	Apixaban	27	suppressed
Pregabalin	Pregabalin	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	26	14
Ozempic	Semaglutide	26	suppressed
Spironolactone	Spironolactone	26	13
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	26	suppressed
Fluticasone Propionate	Fluticasone Propionate	25	suppressed
Carvedilol	Carvedilol	24	12
Humulin R	Insulin Regular, Human	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Lovastatin	Lovastatin	23	suppressed
Tradjenta	Linagliptin	23	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	18
Lactulose	Lactulose	21	13
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	20
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Alvesco	Ciclesonide	19	11
Clonidine Hcl	Clonidine Hcl	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Montelukast Sodium	Montelukast Sodium	19	suppressed
Mupirocin	Mupirocin	19	15
Temazepam	Temazepam	19	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	17	suppressed
Sertraline Hcl	Sertraline Hcl	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Betamethasone Valerate	Betamethasone Valerate	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Baclofen	Baclofen	15	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	14	12
Sitagliptin	Sitagliptin	14	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	13	suppressed
Labetalol Hcl	Labetalol Hcl	13	suppressed
Naproxen	Naproxen	13	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	13	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	12
Nystatin	Nystatin	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed
Xifaxan	Rifaximin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error